February 11, 2021 01:26 PM EST
Manufacturing

End­points Man­u­fac­tur­ing: Lon­za drops in­gre­di­ents biz in $4.7B sale; Touch­light's 'dog­gy­boneD­NA' looks to rewrite rules of ther­a­peu­tic DNA

Conner Mitchell

In a CD­MO in­dus­try flush with cash from Covid-19, the rich keep get­ting rich­er — but that doesn’t mean the top dogs aren’t look­ing for op­por­tu­ni­ties …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Rev­o­lu­tion Med­i­cines breaks ground in chal­leng­ing pan­cre­at­ic can­cer with two RAS drugs

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Up­dat­ed: Pfiz­er's ac­tivist says board must 'hold man­age­ment ac­count­able' for R&D short­com­ings

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

Iterum wins ap­proval for new oral an­tibi­ot­ic for UTIs. Now it wants a part­ner

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times